Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Global Urinalysis Test Market Driven by Increasing Prevalence of Chronic Kidney Disease and Diabetes

By LabMedica International staff writers
Posted on 14 Apr 2023

The global urinalysis test market is growing due to factors such as the rising prevalence of chronic diseases like chronic kidney disease and diabetes, an increase in the geriatric population, and heightened awareness about the importance of regular health checkups. However, market growth is hindered by a shortage of skilled laboratory technicians. Nonetheless, the development of advanced urine analyzers is expected to create new growth opportunities in the near future. As a result, the global urinalysis test market, valued at USD 3.19 billion in 2021, is projected to experience a CAGR of 6.7% from 2022 to 2031, reaching USD 6.12 billion by 2031. These are the latest findings of Allied Market Research (Portland, OR, USA), a market research firm.

The COVID-19 pandemic adversely impacted the global urinalysis test market, as demand for urinalysis devices and consumables decreased due to lower hospitalization rates. Furthermore, sales of urinalysis tests declined during the early stages of the pandemic, and reduced hospital visits for urinalysis tests led to a decline in the adoption of urinalysis devices, thereby hampering market growth. However, the market has gradually recovered and is expected to grow steadily, primarily driven by the increasing incidence of urological disorders.

In 2021, the consumables segment held the largest share of the global urinalysis test market, accounting for over three-fourths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also projected to register the fastest CAGR of 6.9% during this time, owing to technological advancements in urinalysis consumables and high adoption of reagents and strips.

The disease screening segment held the largest share of the global urinalysis test market in 2021, accounting for over half of total revenue, and is expected to remain dominant throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, mainly due to increased adoption of urinalysis devices for disease screening.

In 2021, the diagnostic laboratories segment accounted for the largest share of the global urinalysis test market, contributing around two-fifths of total revenue, and is expected to maintain its dominance throughout the forecast period. This segment is also expected to register the fastest CAGR of 7% during this time, primarily due to an increase in the prevalence of chronic diseases such as diabetes and kidney disease, which has led to a surge in demand for urinalysis tests among diagnostic laboratories.


Regionally, North America held the largest share of the global urinalysis test market in 2021, accounting for over two-fifths of total revenue, and is likely to continue dominating the market during the forecast period. Factors such as easy availability of diagnostic products, well-developed healthcare infrastructure, increased awareness about early disease diagnosis, and higher adoption of advanced diagnostic tools drive the growth of the North American urinalysis test market. However, the Asia-Pacific urinalysis test market is expected to register the fastest CAGR of 7.4% during the forecast period, driven by increased health awareness, development in healthcare infrastructure, and a surge in awareness of preventive healthcare in the region.

Related Links:
Allied Market Research


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.